A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

Longer-acting glucagon-like peptide-1 (GLP-1) receptor agonists and devices have been recently developed and include once-weekly exenatide, dulaglutide, albiglutide, semaglutide and miniosmotic ...

Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes A Review of Current Literature ...

Various glucagon-like peptide-1 agonists are in use or in the licensing process, including exenatide, liraglutide, albiglutide, taspoglutide, lixisenatide and LY2189265. Seventeen randomised ...

Albiglutide contains a GLP-1 dimer fused to albumin, with an alanine to glycine substitution at position 2 enabling DPP-4 resistance, 11 whereas dulaglutide is a DPP-4–resistant GLP-1R agonist with a ...

In the past few decades, advancements in protein engineering, biotechnology, and structural biochemistry have resulted in the discovery of various techniques that enhanced the production yield of ...

Diabetes is one of the most important comorbidities linked to the severity of all three known human pathogenic coronavirus infections, including severe acute respiratory syndrome coronavirus 2.

The HARMONY OUTCOMES trial assessed the cardiovascular efficacy of albiglutide in patients with type 2 diabetes at high cardiovascular risk. Participants were randomized to receive albiglutide (30–50 ...